"The ENBALV trial provides the first large-scale evidence on the use of direct oral anticoagulants in low-risk patients early after bioprosthetic valve surgery," said lead investigator Chisato ...

CHICAGO, IL—Following bioprosthetic valve surgery, anticoagulation with edoxaban (Savaysa; Daiichi Sankyo) is as effective as warfarin, although this strategy might come at a higher cost of bleeding, ...

Opens in a new tab or window CHICAGO -- Edoxaban (Savaysa) appeared at least on par with warfarin for 12-week thromboembolic prophylaxis after bioprosthetic valve surgical implant in a Japanese ...

The ENBALV study provided the first large-scale evidence of the use of DOACs in patients who receive early anticoagulant therapy after bioprosthetic valve surgery. However, the evidence appears ...

People who receive a mechanical heart valve require lifelong anticoagulant therapy to prevent thrombus (blood clot) formation on the valve. Patients who receive a bioprosthetic (made with human or ...

formation on the valve. Patients who receive a bioprosthetic (made with human or animal tissue) heart valve typically need anticoagulants for three to six months after surgery. The standard ...

NewZNew - Fortis Mohali  Successfully Performs Transcatheter Mitral Valve Replacement on 81-Year-Old Patient: Fortis Hospital ...

Edoxaban was comparable to warfarin in preventing stroke or systemic embolism and intracardiac thrombus in patients with non-valvular atrial fibrillation (AFib) within three months after bioprosthetic ...